Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Journal Mobile Options
Table of Contents
Vol. 2, Suppl. 1, 2009
Issue release date: February 2009
Section title: Paper
Obes Facts 2009;2:8–10
(DOI:10.1159/000198239)

Sleeve Gastrectomy as a Single-Stage Bariatric Operation: Indications and Limitations

Daskalakis M. · Weiner R.A.
Center for Minimal-Invasive Surgery, Department of General and Bariatric Surgery, Krankenhaus Sachsenhausen, Frankfurt/M., Germany
email Corresponding Author

Prof. Dr. med. Rudolf A. Weiner, Chirurgische Klinik, Krankenhaus Sachsenhausen, Schulstraße 31, 60594 Frankfurt, Germany, Tel. +49 69 66 05-11 31, Fax -12 03, rweiner@khs-ffm.de

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Abstract

Sleeve gastrectomy (SG) was initially described as a first-step procedure followed by either biliopancreatic diversion with duodenal switch or Roux-en-Y gastric bypass in super-super-obese patients. Multiple recent reports have documented SG as single therapy in the treatment of morbid obesity. However, the indications for this procedure are still under evaluation. Accumulating data demonstrate that SG can be an effective and safe procedure for super-super-obese or high-risk patients either as a single operation or as abridge to more definitive surgery. SG can also be performed in patients who require anti-inflammatory medication or in patients with conditions such as Crohn’s disease, cirrhosis, anemia, or severe osteoporosis which preclude intestinal bypass. Furthermore, SG represents not only a safe alternative for morbidly obese patients on anticoagulant medication or immunosuppressive agents but also for those with multiple intra-abdominal adhesions or after failed gastric banding. In addition, SG can be performed safely in morbid obese adolescents. The main limitation of this novel bariatric procedure is the lack of long-term data on sustained weight loss and resolution of obesity related comorbidities. Moreover, the fact that SG is an irreversible operation adds to its weakness as abariatric procedure,at least until definitive results concerning its efficacy are obtained. SG is effective and safe as a single-stage procedure for certain cohorts of patients. However, the broad application of SG as a single-stage procedurein the bariatric field can be established only if the procedure is standardized and longterm results are available.

© 2009 S. Karger AG, Basel


Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: March 18, 2009
Issue release date: February 2009

Number of Print Pages: 3
Number of Figures: 0
Number of Tables: 0

ISSN: 1662-4025 (Print)
eISSN: 1662-4033 (Online)

For additional information: http://www.karger.com/OFA


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.